Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Abstract Text:

M Mathur,H H Samuels,

A subset of papillary renal cell carcinomas (RCC) is characterized by the expression of a TFE3 fusion protein, where the fusion partner can be any of the several proteins identified so far such as PSF (PTB associated splicing factor), NonO, PRCC, CLTC and ASPL. These proteins result from chromosomal translocations involving the TFE3 gene located on the X chromosome. Our present study documents the central role of PSF-TFE3 in oncogenic transformation. We show that the inhibition of PSF-TFE3 expression through siRNA or shRNA leads to impaired growth, proliferation, invasion potential and long-term survival of UOK-145 papillary renal carcinoma-derived cells, which endogenously express PSF-TFE3. The oncogenic potential of PSF-TFE3 became evident by stable expression of PSF-TFE3 in NIH-3T3 mouse fibroblast cells, which leads to the acquisition of anchorage-independent growth as revealed by soft agar assay. In addition, the expression of PSF-TFE3 in normal renal proximal tubular epithelial cells from where such tumors originate leads to dedifferentiation and loss of some key functional proteins, which may reflect an initial step in the multistep process of tumor development. This suggests that the expression of PSF-TFE3 in renal epithelial cells plays an important role in the initiation and maintenance of oncogenic phenotype in papillary RCC.

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Publishing Authors By Initials

M Mathur,HH Samuels,

For similar proteins: carrier proteins: rna-binding proteins research abstracts see: proteins: carrier proteins: rna-binding proteins research

PUBMED ID PMID:

MEDLINE DATE:

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Oncogene

VOLUME: 26

Page Numbers: 277-83

Journal Abbreviation: Oncogene

ISSN: 0950-9232

DAY: 10

MONTH: 07

YEAR: 2006

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8711562

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Keywords Mesh Terms:

KEYWORDS: RNA-Binding Proteins

MESH TERMS: physiology

Chemical & Substance for Abstract: Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Information

Substance Name: TFE3 protein, human

Registry Number: 0

Grant and Affiliation Information for Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.

AFFILIATION: Department of Pharmacology, New York University School of Medicine, New York, NY 10016, USA. mathum01@med.nyu.edu

Country: England

AGENCY: United States NIDDK

GRANT: DK16636

ACRONYM: DK

MEDLINETA: Oncogene

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas Related Publications

• Artificial regulation of ospC expression in Borrelia burgdorferi.
• California surveillance for pesticide-related illness and injury: coverage, bias, and limitations.
• Cancer chemotherapeutic response and intravenous hyperalimentaion.
• Characterization of Arabidopsis ABCG11/WBC11, an ATP binding cassette (ABC) transporter that is required for cuticular lipid secretion.
• Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma.
• Clozapine use in a forensic population in a New South Wales prison hospital.
• Combination vincristine (NSC-67574) and hydroxyurea (NSC-32065) for metastatic renal carcinoma.
• Early effects of testosterone propionate on the seminal vesicles of castrate rats.
• Farnesyl pyrophosphate is a novel transcriptional activator for a subset of nuclear hormone receptors.
• Genetics of cholesterol and lipoprotein metabolism.
• Gill Samuels.
• History of safe use as applied to the safety assessment of novel foods and foods derived from genetically modified organisms.
• Industrial accidents and peripheral vascular diseases.
• Influence of previous diet on metabolism during fasting.
• Intrathecal methotrexate (NSC-740) therapy for brain tumors in children.
• Meeting the health needs of rural America--the Kirksville mission.
• Mitochondrial AZT metabolism.
• Necrosis of intraocular tissues.
• Nuclear receptor coregulator (NRC): mapping of the dimerization domain, activation of p53 and STAT-2, and identification of the activation domain AD2 necessary for nuclear receptor signaling.
• PARTICIPATION OF THE OCULAR APPENDAGES IN SYMPATHETIC OPHTHALMIA AND ITS BEARING ON ENUCLEATION.
• Psychiatrists' ascertained treatment needs for mental disorders in a population-based sample.
• Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.
• SPECTROFLUORIMETRIC MEASUREMENT OF 1,3-DIAMINO-5-METHYLPHENAZINIUM CHLORIDE (NSC-33419) IN URINE.
• Selection against Pathogenic mtDNA Mutations in a Stem Cell Population Leads to the Loss of the 3243A-->G Mutation in Blood.
• Sleep, recovery, and performance: the new frontier in high-performance athletics.
• Temperature-induced regulation of RpoS by a small RNA in Borrelia burgdorferi.
• The application of post-market monitoring to novel foods.
• The effects of promazine on psychiatric symptoms.
• Thiopropazate hydrochloride (dartal) chemotherapy for emotional disorders; a clinical evaluation.
• Varieties of dual-process theory for probabilistic reasoning.